Enzon Pharmaceuticals, Inc. is a small OTC-traded biopharmaceutical company focused on developing molecules that influence melanocortin receptors for targeted therapies.

# Enzon Pharmaceuticals, Inc. Company Summary

**Overview:**
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company’s primary operations involve developing and licensing pharmaceutical products, with a focus on innovative drug delivery and targeted therapies.

**Key Details:**
- **Business Focus:** Biopharmaceuticals, specifically molecules that influence melanocortin receptors.
- **Number of Customers:** Not explicitly specified.
- **Number of Employees:** Not specified.
- **Revenue:** Not disclosed.
- **Income:** Not disclosed.

**Corporate Governance & Structure:**
- **Executive Management:** Led by Chief Executive Officer, Richard L. Feinstein, who has served since February 2021.
- **Board of Directors:** Composed of five members, including Chairman Randolph C. Read, directors Jordan Bleznick, Jaffery (Jay) A. Firestone, Stephen T. Wills, and Chief Executive Officer Richard L. Feinstein.
- **Shareholders:** Significant ownership held by Carl C. Icahn and affiliated entities holding approximately 48.6% of voting stock, with a total of 74,214,603 shares outstanding as of April 28, 2025.
- **Stock Listing:** The company's common stock, with a par value of $0.01 per share, is not listed on Nasdaq or any major exchange but is traded OTCQX at approximately $0.18 per share.

**Financials:**
- The document does not specify current financial performance, revenue, net income, or total assets.

**Additional Notes:**
- The company maintains policies on insider trading, related-party transactions, and corporate governance.
- No financial statements are included in this report, and specific financial figures are not provided.
- The company has no current equity compensation plans or outstanding awards.
- The company reported aggregate market value of non-affiliate-held shares at approximately $6.8 million as of June 28, 2024.

**Summary:**
Enzon Pharmaceuticals, Inc. is a small, OTC-traded biopharmaceutical company specializing in molecule-based therapies affecting melanocortin receptor activity. Its corporate structure includes notable ownership by Carl Icahn, with a focus on strategic licensing and development rather than extensive commercial sales or large-scale manufacturing.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for serious diseases, particularly cancer.

# Enzon Pharmaceuticals, Inc. Overview

### Business Description
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of therapeutics for the treatment of diseases. The company has historically been involved in the production of a range of pharmaceutical products, including injectable drugs and specialty products targeting cancer and other serious illnesses. Currently, Enzon is actively seeking to leverage its expertise in drug development to explore new business opportunities in various therapeutic areas.

### Key Details

- **Number of Employees**: Enzon Pharmaceuticals does not currently employ a traditional workforce. The company operates with a streamlined team supported by consultants. The principal executive officer, Richard L. Feinstein, serves as the Chief Executive Officer, Chief Financial Officer, and Secretary.

- **Revenue**: As of the fiscal year ended December 31, 2023, specific revenue figures are not disclosed in the excerpt provided, reflecting a possible low operational status or a shift in business focus.

- **Income**: The company's financial standing is not detailed explicitly. However, the summary compensation table indicates that the CEO did not receive a base salary for fiscal years 2022 and 2023, which might suggest limited income generation or restructuring efforts within the company.

### Customer Base
Information regarding the number of customers is not specified in the document. The customer base may primarily consist of healthcare institutions, pharmacies, and possibly direct-to-consumer channels, depending on the product offerings that Enzon Pharmaceuticals holds, though specific details are not available.

### Market Position
Previously, Enzon was notable in the biopharmaceutical industry for its niche in specialty pharmaceuticals, particularly with a focus on cancer therapies. Still, changes over time have largely influenced its operational strategy. Given the extensive ownership by industry figure Carl C. Icahn and associated entities, the company leverages significant investment and strategic direction that shapes its market endeavors.

### Strategic Focus
- The company is currently focused on exploring new therapeutic areas and may involve partnerships, consulting arrangements, or investment strategies rather than extensive operational drug development.
- Enzon Pharmaceuticals utilizes its expertise in drug development and compliance to position itself strategically for future opportunities in the biopharmaceutical landscape.

### Conclusion
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company transitioning its focus and operational model in the evolving landscape of drug development. While precise figures related to revenue and the customer base are not available, the company's leadership, market strategies, and specialist focus within oncology hint at a continuing effort to redefine its role in the biopharmaceutical sector.


ENZON PHARMACEUTICALS, INC.

10-K / April 28, 2025

10-K / April 26, 2024

10-K / April 28, 2025

Enzon Pharmaceuticals, Inc. Company Summary